Introducing the First Nano-Antibody Therapeutic for Chikungunya Virus Infection

Abstract

The Chikungunya virus has caused numerous epidemics in recent decades. The initial phase of the illness is severe and disabling, leading to joint pain and long-lasting joint problems. It can also result in nervous system issues and, in severe cases, encephalomyelitis in older individuals. While a vaccine was approved last year, effective treatment is still unavailable. However, a cell-penetrating nano-antibody has been designed and is currently in development. Laboratory studies show that it can inhibit the virus by up to 99% (with an EC50 of 5.05 μM). This new compound is a STAT3 inhibitor, and it is effective against several other viruses. Effective treatment of viral infections is essential to prevent the development of chronic inflammatory conditions that may lead to the onset of serious diseases, including neurodegenerative and other severe conditions.